Engage and Emerge
Two global phase 3 clinical trials for people experiencing symptoms of early Alzheimer’s disease
To evaluate the safety and potential effectiveness of an investigational drug (BIIB037) in people experiencing symptoms of early Alzheimer’s disease, such as problems with memory or thinking clearly.
The investigational drug
Thought to target and reduce harmful amyloid plaques (abnormal deposits) that form in the brains of people with Alzheimer’s disease. Researchers will ask if BIIB037 can remove the plaques and potentially slow the disease’s progression.
Key eligibility criteria
- Men and women
- 50-85 years old
- Experiencing symptoms that might be related to early Alzheimer’s disease, such as problems with memory or thinking clearly
- Have a study partner who can attend certain appointments and provide information about the study participant’s health
- Approximately 1 year 6 months
- Optional potential long-term extension study